Cancer is a significant public health concern worldwide, which results in millions of deaths each year. The standard cure routine for cancer is surgery, and nowadays, radiotherapy or a hadrontherapy. Depending on the type of cancer, patients may undergo additional treatment, including targeted therapy. A combination of radio- or hadron-therapy with proper drug treatment can inhibit the proliferation of cancer cells and thus can significantly improve survival rates. This is because the interaction of radiation on those drugs can lead to their fragmentation, which additionally increases the number of reactive species that interact with the adjacent medium. For example, anthracyclines, a class of drugs build on tetrahydropyran ring, are broad-spectrum antitumor agents that induce, among other things, indirect damage to DNA via reactions involving reactive oxygen species.
Autorzy
- mgr inż. Michał Jurkowski link otwiera się w nowej karcie ,
- Antti Kivimaki,
- Robert Richter,
- dr hab. Tomasz Wąsowicz link otwiera się w nowej karcie
Informacje dodatkowe
- Kategoria
- Publikacja w czasopiśmie
- Typ
- artykuły w czasopismach
- Język
- angielski
- Rok wydania
- 2020
